All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 5% PD-L1 > 5% stage IIIb stage IIIc stage IV (metastatic) stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - (neo)adjuvant (NA), nivolumab alone vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 238, 2017 0.87 [0.66; 1.14]
0.87 [0.66 ; 1.14 ] CheckMate 238, 2017 1 0% 906 NA not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
0.73 [0.56 ; 0.96 ] CheckMate 238, 2017 1 0% 735 NA not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
0.71 [0.59 ; 0.85 ] CheckMate 238, 2017 1 0% 906 NA not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.50 [1.26; 4.97]
1.22 [0.33 ; 4.58 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 92% 1,021 low not evaluable AE (any grade)detailed results CheckMate 238, 2017 0.49 [0.20; 1.23]
0.49 [0.20 ; 1.23 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE (grade 3-4)detailed results CheckMate 238, 2017 0.28 [0.21; 0.37]
0.28 [0.21 ; 0.37 ] CheckMate 238, 2017 1 0% 905 NA not evaluable AE leading to death (grade 5)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 238, 2017 0.15 [0.10; 0.21]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.14 [0.10 ; 0.19 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.11 [0.07 ; 0.16 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable SAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.27 [0.12; 0.59]
0.27 [0.12 ; 0.59 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable SAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.29 [0.13; 0.63]
0.29 [0.13 ; 0.63 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable STRAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.08; 0.41]
0.18 [0.08 ; 0.41 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable STRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.21 [0.09; 0.52]
0.21 [0.09 ; 0.52 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE (any grade)detailed results CheckMate 238, 2017 0.25 [0.15; 0.43]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.20 [0.04; 0.96]
0.25 [0.15 ; 0.40 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.20 [0.14; 0.27]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.15 [0.07; 0.34]
0.19 [0.14 ; 0.26 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.42 [0.04 ; 4.82 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 238, 2017 0.12 [0.08; 0.17]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.11 [0.08 ; 0.16 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.09 [0.05; 0.15]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.09 [0.05 ; 0.14 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.02; 14.96]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.67 [0.05 ; 8.74 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.50 [0.11 ; 2.28 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Alopecia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4.04 [0.18; 91.59]
1.11 [0.15 ; 8.11 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 7% 1,016 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.03; 2.24]
0.25 [0.03 ; 2.24 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.16 [0.01 ; 3.19 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Cough TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.99 [0.18 ; 22.17 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.15 [0.07; 0.34]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.23 [0.05 ; 1.11 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 37% 1,016 low not evaluable Dizziness TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dry skin TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.02; 1.61]
0.18 [0.02 ; 1.61 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.09; 2.74]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.56 [0.12 ; 2.65 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.10 [0.05; 0.20]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.11 [0.01; 0.89]
0.10 [0.05 ; 0.20 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.14 [0.02; 1.15]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.22 [0.03 ; 1.38 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Hepatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.30 [0.06; 1.57]
0.30 [0.06 ; 1.57 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.15 [0.07; 0.32]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.13 [0.03; 0.63]
0.15 [0.07 ; 0.29 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
2.01 [0.07 ; 59.97 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 1.00 [0.06; 16.07]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.43 [0.06 ; 3.30 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.04; 0.81]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
0.36 [0.04 ; 3.04 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 37% 1,016 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.50 [0.05; 5.53]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.60 [0.08 ; 4.67 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.02; 0.44]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.19 [0.06 ; 0.60 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 25% 1,016 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.18 [0.07; 0.48]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.05; 0.68]
0.18 [0.08 ; 0.40 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.33 [0.08 ; 1.33 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.05 [0.00; 0.95]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.13 [0.02 ; 1.20 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.98 [0.06 ; 16.10 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6.17 [0.30; 126.14]
6.17 [0.30 ; 126.14 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.98 [0.07 ; 60.31 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
1.48 [0.11 ; 19.37 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Nervous system disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.00 [0.18; 22.72]
2.00 [0.18 ; 22.72 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.10 [0.01; 1.82]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.22 [0.02 ; 2.32 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.25 [0.01; 5.55]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.03 ; 2.20 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 238, 2017 0.35 [0.13; 0.98]
0.35 [0.13 ; 0.98 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] CheckMate 238, 2017 1 0% 905 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.12 [0.01; 2.36]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.26 [0.02 ; 2.75 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 238, 2017 0.18 [0.07; 0.46]
IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.32 [0.03; 3.13]
0.19 [0.08 ; 0.47 ] CheckMate 238, 2017, IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2 0% 1,016 low not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Uveitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-03 17:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 284,70,235
- treatments: 360,719,721,720
